Ajinomoto expands fill-finish capacity

By The Science Advisory Board staff writers

May 25, 2021 -- Ajinomoto Bio-Pharma Services is opening a high-speed, multipurpose fill-finish line in its commercial manufacturing facility located in San Diego, CA.

The fill line, operational this summer, will offer a range of configurations including prefilled syringes, cartridges, and vials with ready-to-use components to minimize component preparation and packaging. The fill suite also houses two formulation suites, one of which is capable of handling flammable (class H) compounds.

Ajinomoto's Optima line uses Skan isolated barrier technology to guarantee the required sterility for fill finish and offers flexibility to meet current good manufacturing practices for clinical and commercial drugs, while in commercial compliance with the U.S. Food and Drug Administration. The high-speed process can move 22,000 syringes per hour through the line, with a batch capacity of over 200,000 syringes.

Ajinomoto to up production of Humanigen's COVID-19 drug
Ajinomoto Bio-Pharma Services and Humanigen are expanding their manufacturing agreement for the fill-finish supply of lenzilumab, an investigational COVID-19...
Ajinomoto introduces new drug manufacturing platform for COVID-19
Ajinomoto Bio-Pharma Services launched Ajility, a flexible drug product manufacturing platform for vaccines and therapies.
Ajinomoto to manufacture COVID-19 drug for Humanigen
Biopharmaceutical contract development and manufacturing firm Ajinomoto has entered into an agreement with Humanigen for the fill-finish supply of lenzilumab....
Trio, Ajinomoto to develop cancer therapeutic
Cancer therapeutics company Trio Pharmaceuticals and biopharmaceutical contract development and manufacturing company Ajinomoto Bio-Pharma Services have...

Copyright © 2021 scienceboard.net


Conferences
Cell Bio 2021
December 11-15
San Diego, California United States
Antibody Engineering and Therapeutics
December 13-17
San Diego, California United States
Connect
Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter